HA
LCTX icon

Hofer & Associates’s Lineage Cell Therapeutics LCTX Stock Holding History

Hofer & Associates’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$484K Buy
+506,460
New +$560K 0.34% 57

Other funds holding LCTX

DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
RCWM
Red Crane Wealth Management San Francisco, California $143M AUM 13.63% 1-Year Est. Return
CWM
Connecticut Wealth Management Farmington, Connecticut $2.73B AUM 14.39% 1-Year Est. Return
CD
Chapin Davis Baltimore, Maryland $520M AUM 117.57% 1-Year Est. Return
FCMT
Founders Capital Management (Texas) Houston, Texas $220M AUM 46.36% 1-Year Est. Return
AP
Anchyra Partners Atlanta, Georgia $477M AUM 34.33% 1-Year Est. Return
EM
ELCO Management New York $213M AUM 25.23% 1-Year Est. Return
PP
Pacifica Partners Surrey, Canada $332M AUM 43.09% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Hofer & Associates's LCTX Position: Q3 2026 in Review

Hofer & Associates opened a new position in Lineage Cell Therapeutics (LCTX) in Q3 2026: 506,460 shares worth $484K. The stake represents 0.34% of the portfolio and ranks #57 among its holdings.

11 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

  • Hofer & Associates held 506,460 shares of Lineage Cell Therapeutics worth $484K as of Q3 2026.
  • Lineage Cell Therapeutics was a new Hofer & Associates position in Q3 2026.
  • Lineage Cell Therapeutics made up 0.34% of Hofer & Associates's portfolio in Q3 2026, its #57 holding.
  • 11 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on Hofer & Associates's 13F filing for Q3 2026, filed 13 Oct 2026.